Although PLS patients do not exhibit severe immunodeficiency, the specific impacts of long-term DPP1 inhibitor use on immune function still need further clarification through large-scale long-term clinical studies (Pillay et al., 2010). The gene discussed is CTSC; the disease is immunodeficiency disease.